Hollsteen
← Meta

Research and development

Flow – sum over the period · $B

QuartersFiscal years

$BResearch and development · Q1 2016: $1.3B · 10-Q 0001326801-16-000067 filed Apr 28, 2016Research and development · Q2 2016: $1.5B · 10-Q 0001326801-17-000038 filed Jul 27, 2017Research and development · Q3 2016: $1.5B · 10-Q 0001326801-17-000053 filed Nov 2, 2017Research and development · Q4 2016: $1.6B · derived · 10-K 0001326801-18-000009 filed Feb 1, 2018Research and development · Q1 2017: $1.8B · 10-Q 0001326801-17-000024 filed May 4, 2017Research and development · Q2 2017: $1.9B · 10-Q 0001326801-17-000038 filed Jul 27, 2017Research and development · Q3 2017: $2.1B · 10-Q 0001326801-17-000053 filed Nov 2, 2017Research and development · Q4 2017: $1.9B · derived · 10-K 0001326801-19-000009 filed Jan 31, 2019Research and development · Q1 2018: $2.2B · 10-Q 0001326801-18-000032 filed Apr 26, 2018Research and development · Q2 2018: $2.5B · 10-Q 0001326801-18-000057 filed Jul 26, 2018Research and development · Q3 2018: $2.7B · 10-Q 0001326801-18-000067 filed Oct 31, 2018Research and development · Q4 2018: $2.9B · derived · 10-K 0001326801-20-000013 filed Jan 30, 2020Research and development · Q1 2019: $2.9B · 10-Q 0001326801-19-000037 filed Apr 25, 2019Research and development · Q2 2019: $3.3B · 10-Q 0001326801-19-000055 filed Jul 25, 2019Research and development · Q3 2019: $3.5B · 10-Q 0001326801-19-000069 filed Oct 31, 2019Research and development · Q4 2019: $3.9B · derived · 10-K 0001326801-21-000014 filed Jan 28, 2021Research and development · Q1 2020: $4.0B · 10-Q 0001326801-20-000048 filed Apr 30, 2020Research and development · Q2 2020: $4.5B · 10-Q 0001326801-20-000076 filed Jul 31, 2020Research and development · Q3 2020: $4.8B · 10-Q 0001326801-20-000084 filed Oct 30, 2020Research and development · Q4 2020: $5.2B · derived · 10-K 0001326801-22-000018 filed Feb 3, 2022Research and development · Q1 2021: $5.2B · 10-Q 0001326801-21-000033 filed Apr 29, 2021Research and development · Q2 2021: $6.1B · 10-Q 0001326801-21-000049 filed Jul 29, 2021Research and development · Q3 2021: $6.3B · 10-Q 0001326801-21-000065 filed Oct 26, 2021Research and development · Q4 2021: $7.0B · derived · 10-K 0001326801-23-000013 filed Feb 2, 2023Research and development · Q1 2022: $7.7B · 10-Q 0001326801-22-000057 filed Apr 28, 2022Research and development · Q2 2022: $8.7B · 10-Q 0001326801-22-000082 filed Jul 28, 2022Research and development · Q3 2022: $9.2B · 10-Q 0001326801-22-000108 filed Oct 27, 2022Research and development · Q4 2022: $9.8B · derived · 10-K 0001326801-24-000012 filed Feb 2, 2024Research and development · Q1 2023: $9.4B · 10-Q 0001326801-23-000067 filed Apr 27, 2023Research and development · Q2 2023: $9.3B · 10-Q 0001326801-23-000093 filed Jul 27, 2023Research and development · Q3 2023: $9.2B · 10-Q 0001326801-23-000103 filed Oct 26, 2023Research and development · Q4 2023: $10.5B · derived · 10-K 0001326801-25-000017 filed Jan 30, 2025Research and development · Q1 2024: $10.0B · 10-Q 0001326801-24-000049 filed Apr 25, 2024Research and development · Q2 2024: $10.5B · 10-Q 0001326801-24-000069 filed Aug 1, 2024Research and development · Q3 2024: $11.2B · 10-Q 0001326801-24-000081 filed Oct 31, 2024Research and development · Q4 2024: $12.2B · derived · 10-K 0001628280-26-003942 filed Jan 29, 2026Research and development · Q1 2025: $12.2B · 10-Q 0001326801-25-000054 filed May 1, 2025Research and development · Q2 2025: $12.9B · 10-Q 0001628280-25-036791 filed Jul 31, 2025Research and development · Q3 2025: $15.1B · 10-Q 0001628280-25-047240 filed Oct 30, 2025Research and development · Q4 2025: $17.1B · derived · 10-K 0001628280-26-003942 filed Jan 29, 2026Research and development · Q1 2026: $17.7B · 10-Q 0001628280-26-028526 filed Apr 30, 2026Research and development · Q2 2026: $21.7B · 10-Q 0001628280-26-050705 filed Jul 30, 20261.321.7Q1 2016Q2 2026Q2 2021
$BResearch and development · Q1 2016: $1.3B · 10-Q 0001326801-16-000067 filed Apr 28, 2016Research and development · Q2 2016: $1.5B · 10-Q 0001326801-17-000038 filed Jul 27, 2017Research and development · Q3 2016: $1.5B · 10-Q 0001326801-17-000053 filed Nov 2, 2017Research and development · Q4 2016: $1.6B · derived · 10-K 0001326801-18-000009 filed Feb 1, 2018Research and development · Q1 2017: $1.8B · 10-Q 0001326801-17-000024 filed May 4, 2017Research and development · Q2 2017: $1.9B · 10-Q 0001326801-17-000038 filed Jul 27, 2017Research and development · Q3 2017: $2.1B · 10-Q 0001326801-17-000053 filed Nov 2, 2017Research and development · Q4 2017: $1.9B · derived · 10-K 0001326801-19-000009 filed Jan 31, 20191.31.9a2.1Q1 2016Q4 2017Q1 2017
Q1 2016
1.3$B
All values (42)
PeriodValue ($B)Status
Q2 202621.7reported
Q1 202617.7reported
Q4 202517.1derived
Q3 202515.1reported
Q2 202512.9reported
Q1 202512.2reported
Q4 202412.2derived
Q3 202411.2reported
Q2 202410.5reported
Q1 202410.0reported
Q4 202310.5derived
Q3 20239.2reported
Q2 20239.3reported
Q1 20239.4reported
Q4 20229.8derived
Q3 20229.2reported
Q2 20228.7reported
Q1 20227.7reported
Q4 20217.0derived
Q3 20216.3reported
Q2 20216.1reported
Q1 20215.2reported
Q4 20205.2derived
Q3 20204.8reported
Q2 20204.5reported
Q1 20204.0reported
Q4 20193.9derived
Q3 20193.5reported
Q2 20193.3reported
Q1 20192.9reported
Q4 20182.9derived
Q3 20182.7reported
Q2 20182.5reported
Q1 20182.2reported
Q4 20171.9derived
Q3 20172.1reported
Q2 20171.9reported
Q1 20171.8reported
Q4 20161.6derived
Q3 20161.5reported
Q2 20161.5reported
Q1 20161.3reported

CSV with all sources · Technical ID: rnd

More metrics for Meta

Value drivers

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Operating income by segment

Sources & calculation
Value
$1.3B
Period
Q1 2016, ended Mar 31, 2016 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Apr 28, 2016 · 0001326801-16-000067
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$1.3BApr 28, 201610-Q 0001326801-16-000067reported · confidence 1. · current